Lymphoepithelioma-like carcinoma of the urinary bladder

Mahul Amin, J. Y. Ro, K. M. Lee, N. G. Ordonez, C. P. Dinney, M. L. Gulley, A. G. Ayala

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

We report the cases of 11 patients who were treated for undifferentiated carcinoma of the urinary bladder with a prominent lymphoid stroma (lymphoepithelioma-like carcinoma [LELC]). The chief complaint of all 11 patients was hematuria. Their ages ranged from 52 to 79 years (mean of 67). All tumors except one invaded the muscle wall and showed the typical syncytial growth pattern of undifferentiated cells with ill-defined cytoplasmic borders, prominent nucleoli, and numerous mitoses. A significant lymphocytic reaction was an essential component of all these tumors. There were three pure LELC tumors without concurrent invasive transitional-cell carcinoma (TCC) or TCC in situ: these cases morphologically simulated large- cell lymphoma. The remainder were mixed TCC and LELC (five predominant and three focal LELC). The tumor cells were immunoreactive for keratin and showed negative results for leukocyte common antigen. The lymphoid population was an admixture of T cells and B cells with a predominance of T cells. Seven patients (four with predominant and three with focal LELC) were treated with various therapeutic methods. Four patients (three with pure and one with predominantly LELC) received only chemotherapy after transurethral resection of the tumor, and follow-up found no evidence of disease for 9-72 months (mean of 38 months). Awareness of an LELC component in a urinary bladder tumor is also important in order to avoid misinterpreting these tumors as malignant lymphoma or severe chronic cystitis. Our data suggest that the pure LELC tumor appears to be morphologically and clinically different from TCC and that it merits recognition as a separate clinicopathologic entity. In addition, there is strong suggestive evidence that it responses to chemotherapy and therefore there is the potential of salvaging bladder function.

Original languageEnglish (US)
Pages (from-to)466-473
Number of pages8
JournalAmerican Journal of Surgical Pathology
Volume18
Issue number5
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Urinary Bladder
Carcinoma
Transitional Cell Carcinoma
Neoplasms
Lymphoma
CD45 Antigens
T-Lymphocytes
Drug Therapy
Cystitis
Carcinoma in Situ
Hematuria
Keratins
Mitosis
Urinary Bladder Neoplasms
B-Lymphocytes
Muscles
Growth
Population

All Science Journal Classification (ASJC) codes

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Cite this

Amin, M., Ro, J. Y., Lee, K. M., Ordonez, N. G., Dinney, C. P., Gulley, M. L., & Ayala, A. G. (1994). Lymphoepithelioma-like carcinoma of the urinary bladder. American Journal of Surgical Pathology, 18(5), 466-473. https://doi.org/10.1097/00000478-199405000-00005

Lymphoepithelioma-like carcinoma of the urinary bladder. / Amin, Mahul; Ro, J. Y.; Lee, K. M.; Ordonez, N. G.; Dinney, C. P.; Gulley, M. L.; Ayala, A. G.

In: American Journal of Surgical Pathology, Vol. 18, No. 5, 01.01.1994, p. 466-473.

Research output: Contribution to journalArticle

Amin, M, Ro, JY, Lee, KM, Ordonez, NG, Dinney, CP, Gulley, ML & Ayala, AG 1994, 'Lymphoepithelioma-like carcinoma of the urinary bladder', American Journal of Surgical Pathology, vol. 18, no. 5, pp. 466-473. https://doi.org/10.1097/00000478-199405000-00005
Amin, Mahul ; Ro, J. Y. ; Lee, K. M. ; Ordonez, N. G. ; Dinney, C. P. ; Gulley, M. L. ; Ayala, A. G. / Lymphoepithelioma-like carcinoma of the urinary bladder. In: American Journal of Surgical Pathology. 1994 ; Vol. 18, No. 5. pp. 466-473.
@article{cb55bb7ea13f4426a56d7b2a7edf5cee,
title = "Lymphoepithelioma-like carcinoma of the urinary bladder",
abstract = "We report the cases of 11 patients who were treated for undifferentiated carcinoma of the urinary bladder with a prominent lymphoid stroma (lymphoepithelioma-like carcinoma [LELC]). The chief complaint of all 11 patients was hematuria. Their ages ranged from 52 to 79 years (mean of 67). All tumors except one invaded the muscle wall and showed the typical syncytial growth pattern of undifferentiated cells with ill-defined cytoplasmic borders, prominent nucleoli, and numerous mitoses. A significant lymphocytic reaction was an essential component of all these tumors. There were three pure LELC tumors without concurrent invasive transitional-cell carcinoma (TCC) or TCC in situ: these cases morphologically simulated large- cell lymphoma. The remainder were mixed TCC and LELC (five predominant and three focal LELC). The tumor cells were immunoreactive for keratin and showed negative results for leukocyte common antigen. The lymphoid population was an admixture of T cells and B cells with a predominance of T cells. Seven patients (four with predominant and three with focal LELC) were treated with various therapeutic methods. Four patients (three with pure and one with predominantly LELC) received only chemotherapy after transurethral resection of the tumor, and follow-up found no evidence of disease for 9-72 months (mean of 38 months). Awareness of an LELC component in a urinary bladder tumor is also important in order to avoid misinterpreting these tumors as malignant lymphoma or severe chronic cystitis. Our data suggest that the pure LELC tumor appears to be morphologically and clinically different from TCC and that it merits recognition as a separate clinicopathologic entity. In addition, there is strong suggestive evidence that it responses to chemotherapy and therefore there is the potential of salvaging bladder function.",
author = "Mahul Amin and Ro, {J. Y.} and Lee, {K. M.} and Ordonez, {N. G.} and Dinney, {C. P.} and Gulley, {M. L.} and Ayala, {A. G.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1097/00000478-199405000-00005",
language = "English (US)",
volume = "18",
pages = "466--473",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Lymphoepithelioma-like carcinoma of the urinary bladder

AU - Amin, Mahul

AU - Ro, J. Y.

AU - Lee, K. M.

AU - Ordonez, N. G.

AU - Dinney, C. P.

AU - Gulley, M. L.

AU - Ayala, A. G.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - We report the cases of 11 patients who were treated for undifferentiated carcinoma of the urinary bladder with a prominent lymphoid stroma (lymphoepithelioma-like carcinoma [LELC]). The chief complaint of all 11 patients was hematuria. Their ages ranged from 52 to 79 years (mean of 67). All tumors except one invaded the muscle wall and showed the typical syncytial growth pattern of undifferentiated cells with ill-defined cytoplasmic borders, prominent nucleoli, and numerous mitoses. A significant lymphocytic reaction was an essential component of all these tumors. There were three pure LELC tumors without concurrent invasive transitional-cell carcinoma (TCC) or TCC in situ: these cases morphologically simulated large- cell lymphoma. The remainder were mixed TCC and LELC (five predominant and three focal LELC). The tumor cells were immunoreactive for keratin and showed negative results for leukocyte common antigen. The lymphoid population was an admixture of T cells and B cells with a predominance of T cells. Seven patients (four with predominant and three with focal LELC) were treated with various therapeutic methods. Four patients (three with pure and one with predominantly LELC) received only chemotherapy after transurethral resection of the tumor, and follow-up found no evidence of disease for 9-72 months (mean of 38 months). Awareness of an LELC component in a urinary bladder tumor is also important in order to avoid misinterpreting these tumors as malignant lymphoma or severe chronic cystitis. Our data suggest that the pure LELC tumor appears to be morphologically and clinically different from TCC and that it merits recognition as a separate clinicopathologic entity. In addition, there is strong suggestive evidence that it responses to chemotherapy and therefore there is the potential of salvaging bladder function.

AB - We report the cases of 11 patients who were treated for undifferentiated carcinoma of the urinary bladder with a prominent lymphoid stroma (lymphoepithelioma-like carcinoma [LELC]). The chief complaint of all 11 patients was hematuria. Their ages ranged from 52 to 79 years (mean of 67). All tumors except one invaded the muscle wall and showed the typical syncytial growth pattern of undifferentiated cells with ill-defined cytoplasmic borders, prominent nucleoli, and numerous mitoses. A significant lymphocytic reaction was an essential component of all these tumors. There were three pure LELC tumors without concurrent invasive transitional-cell carcinoma (TCC) or TCC in situ: these cases morphologically simulated large- cell lymphoma. The remainder were mixed TCC and LELC (five predominant and three focal LELC). The tumor cells were immunoreactive for keratin and showed negative results for leukocyte common antigen. The lymphoid population was an admixture of T cells and B cells with a predominance of T cells. Seven patients (four with predominant and three with focal LELC) were treated with various therapeutic methods. Four patients (three with pure and one with predominantly LELC) received only chemotherapy after transurethral resection of the tumor, and follow-up found no evidence of disease for 9-72 months (mean of 38 months). Awareness of an LELC component in a urinary bladder tumor is also important in order to avoid misinterpreting these tumors as malignant lymphoma or severe chronic cystitis. Our data suggest that the pure LELC tumor appears to be morphologically and clinically different from TCC and that it merits recognition as a separate clinicopathologic entity. In addition, there is strong suggestive evidence that it responses to chemotherapy and therefore there is the potential of salvaging bladder function.

UR - http://www.scopus.com/inward/record.url?scp=0028210310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028210310&partnerID=8YFLogxK

U2 - 10.1097/00000478-199405000-00005

DO - 10.1097/00000478-199405000-00005

M3 - Article

VL - 18

SP - 466

EP - 473

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 5

ER -